Key facts
- BioOra’s last known valuation is $44.0M (Oct 2025).
- It has raised $15.8M; the latest was Early Stage VC ($8.8M) in Oct 2025.
- Notable investors include Ngāi Tahu Holdings, Angel Investors Marlborough, Booster Innovation Fund, Bridgewest Ventures, Callaghan Innovation — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for BioOra
- ·The full record, as it builds
Funding rounds
No funding rounds for BioOra are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioOra
Manufacturer of an automated CAR T-cell therapy manufacturing platform designed to improve accessibility, safety, speed, and affordability of cancer treatment. The company offers exclusive rights to commercialize Atla-Cel, a CAR-T therapy with an improved safety profile and comparable efficacy targeting non-Hodgkin lymphoma and other blood cancers, enabling cancer patients in New Zealand, Australia, and other underserved regions to access locally manufactured cell therapies with reduced wait times and lower treatment costs.
- Sector
- Healthcare
- HQ
- Wellington, New Zealand
- Founded
- 2021
- Employees
- 48
- Website
- bioora.com/
- Ownership
- Privately Held (backing)
BioOra doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioOra shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioOra in its N-PORT filings yet. We sweep new filings monthly.